A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary

Annals of Internal Medicine

Volumn 132, Issue 9, 2000, Pages 743-756

  Williams Jr , John W ^a   Mulrow, Cynthia D ^a   Chiquette, Elaine ^b   Noël, Polly Hitchcock ^b   Aguilar, Christine ^a   Cornell, John ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DOXEPIN; FENGABINE; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GEPIRONE; IMIPRAMINE; IPSAPIRONE; MAPROTILINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PHENELZINE; RITANSERIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TANDOSPIRONE; TRANYLCYPROMINE; TRAZODONE; TRIMIPRAMINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG EFFICACY; FEMALE; HUMAN; HYPERICUM PERFORATUM; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK BENEFIT ANALYSIS;

EID: 0034595401     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-132-9-200005020-00011     Document Type: Article

References (116)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994;51:8-19.
2. Regier DA, Boyd JH. Burke JD Jr, Rae DS, Myers JK, Kramer M, et al. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45:977-86.
3. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. Depression: a neglected major illness. J Clin Psychiatry. 1993;54:419-24.
4. Murray CJ, Lopez AD. The Global Burden of Disease. Cambridge, MA: Harvard Univ Pr; 1996.
5. Murray CJ, Lopez AD. Evidence-based health policy - lessons from the Global Burden of Disease Study. Science. 1996;274:740-3.
6. Depression Guideline Panel. Depression in Primary Care. v 1. Detection and Diagnosis. Clinical Practice Guideline No. 5. Rockville, MD: U.S. Department of Health and Human Services, Agency for Heath Care Policy and Research; 1993. AHCPR Publication No. 93-0550.
7. Depression Guideline Panel. Depression in Primary Care. v 2. Treatment of Major Depression. Clinical Practice Guideline No. 5. Rockville, MD: U.S. Department of Health and Human Services, Agency for Heath Care Policy and Research; 1993. AHCPR Publication No. 93-0551.
8. Trinidade E, Menon D. Selective Serotonin Reuptake Inhibitors (SSRIs) for Major Depression. Part I. Evaluation of the Clinical Literature. CCOHTA Report 1997:3E-1997-4E. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1997.
9. Hotopf M, Lewis G, Normand C. Are SSRIs a cost-effective alternative to tricyclics? Br J Psychiatry. 1996;168:404-9.
10. North of England Evidence-Based Guideline Development Project. The Choice of Antidepressants for Depression in Primary Care: Evidence-Based Clinical Practice Guideline. Newcastle upon Tyne: Centre for Health Services Research, Univ of Newcastle upon Tyne; 1998.
11. Practice guideline for adult major depressive disorder in adults. Am J Psychiatry. 1993;150(4 Suppl):iii-25.
12. Thase ME, Greenhouse JB, Frank E, Reynolds CF 3d, Pilkonis PA, Hurley K, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Arch Gen Psychiatry. 1997; 54:1009-15.
13. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ. 1995;310:1433-8.
14. Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies. J Clin Psychopharmacol. 1995;15(4 Suppl 2): 16S-23S.
15. Anton SF, Robinson DS, Roberts DL, Kensler TT, English PA, Archibald DG. Long-term treatment of depression with nefazodone. Psychopharmacol Bull. 1994;30:165-9.
16. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry. 1995;56:519-25.
17. Brown C, Schulberg HC. The efficacy of psychosocial treatments in primary care. A review of randomized clinical trials. Gen Hosp Psychiatry. 1995;17: 414-24.
18. Byrne MM. Meta-analysis of early phase II studies with paroxetine in hospitalized depressed patients. Acta Psychiatr Scand Suppl. 1989;350:138-9.
19. Churchill R, Wessely S, Lewis G. A systematic review and meta analysis of the effects of combining pharmacotherapy and psychotherapy for the treatment of depression [Protocol]. The Cochrane Library. Update 1998;2.
20. Claghorn JL, Kiev A, Rickels K, Smith WT, Dunbar GC. Paroxetine versus placebo: a double-blind comparison in depressed patients. J Clin Psychiatry. 1992;53:434-8.
21. Cucherat M, Cialdella P. Meta-analysis of therapeutic trials: applications in psychiatry [La meta-analyse des essais therapeutiques: applications en psychiatrie]. Encephale. 1996;22:378-87.
22. DeVane CL, Sallee FR. Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience. J Clin Psychiatry. 1996;57:55-66.
23. Delini-Stula A, Mikkelsen H, Angst J. Therapeutic efficacy of antidepressants in agitated anxious depression - a meta-analysis of moclobemide studies. J Affect Disord 1995;35:21-30.
24. Dunbar GC. Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology. 1995;51:137-44.
25. Dunbar GC, Claghorn JL, Kiev A, Rickels K, Smith WT. A comparison of paroxetine and placebo in depressed outpatients. Acta Psychiatr Scand. 1993;87:302-5.
26. Entsuah AR, Rudolph RL, Chitra R. Effectiveness of venlafaxine treatment in a broad spectrum of depressed patients: a meta-analysis. Psychopharmacol Bull. 1995;31:759-66.
27. Fawcett J, Marcus RN, Anton SF, O'Brien K, Schwiderski U. Response of anxiety and agitation symptoms during nefazodone treatment of major depression. J Clin Psychiatry. 1995;56(Suppl 6):37-42.
28. Freemantle N, Long A, Mason J, Sheldon T, Song F, Watson P, et al. The treatment of depression in primary care. Effective Health Care. 1993;5.
29. Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors: an overview of their comparative efficacy in the treatment of depressive disorder [Protocol]. The Cochrane Library. Update 1998;2.
30. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry. 1995;56:128-36.
31. Greenberg RP, Bornstein RF, Greenberg MD, Fisher S. A meta-analysis of antidepressant outcome under "blinder" conditions. J Consult Clin Psychol. 1992;60:664-9.
32. Greenberg RP, Bornstein RF, Zborowski MJ, Fisher S, Greenberg MD. A meta-analysis of fluoxetine outcome in the treatment of depression. J Nerv Ment Dis. 1994;182:547-51.
33. Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP, Geddes JR, et al. Systematic review of treatment discontinuation in randomised controlled trials comparing the selective serotonin reuptake inhibitors and other new generation antidepressants with tricyclic and related antidepressants [Protocol]. The Cochrane Library. Update 1998;2.
34. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry. 1997;170:120-7.
35. Hotopf M, Lewis G, Normand C. Putting trials on trial - the costs and consequences of small trials in depression: a systematic review of methodology. J Epidemiol Community Health. 1997;51:354-8.
36. Kasper S. Clinical efficacy of mirtazapine: a review of meta-analyses of pooled data. Int Clin Psychopharmacol. 1995;10(Suppl 4):25-35.
37. Kasper S, Pletan Y, Solles A, Tournoux A. Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression: a summary of clinical trial results. Int Clin Psychopharmacol. 1996;11(Suppl 4):35-9.
38. Lima MS, Hotopf M. A comparison of active drugs for the treatment of dysthymia [Protocol]. The Cochrane Library. Update 1998;2.
39. Lima MS, Moncrieff J. A comparison of drugs versus placebo for the treatment of dysthymia: a systematic review. The Cochrane Library. Update 1998;2.
40. Linde K, Mulrow CD, Fischer P. St. John's wort for depression [Protocol]. The Cochrane Library. Update 1998;2.
41. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253-8.
42. McCusker J, Cole M, Keller E, Bellavance F, Berard A. Effectiveness of treatments of depression in older ambulatory patients. Arch Intern Med. 1998;158:705-12.
43. Montgomery SA. Selecting the optimum therapeutic dose of serotonin reuptake inhibitors: studies with citalopram. Int Clin Psychopharmacol. 1995; 10(Suppl 1):23-7.
44. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol. 1994;9:47-53.
45. Montgomery SA, Kasper S. Comparison of compliance between serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. Int Clin Psychopharmacol. 1995;9(Suppl 4):33-40.
46. Montgomery SA, Pedersen V, Tanghøj P, Rasmussen C, Rioux P. The optimal dosing regimen for citalopram - a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 1994;9(Suppl 1):35-40.
47. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol. 1997; 12:99-108.
48. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ. 1993;306:683-7.
49. Stahl S, Zivkov M, Reimitz PE, Panagides J, Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled, efficacy and safety studies of mirtazapine versus amitriptyline in major depression. Acta Psychiatr Scand Suppl. 1997;391:22-30.
50. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry. 1996;29:87-96.
51. Steffens DC, Krishnan KR, Helms MJ. Are SSRIs better than TCAs? Comparison of SSRIs and TCAs: a meta-analysis. Depress Anxiety. 1997;6:10-8.
52. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination. Interactions and therapeutic uses. Br J Psychiatry. 1995;167:575-80.
53. Wilson K, Mottram P, Sivananthan A. A review of antidepressant drug trials in the treatment of older depressed people [Protocol]. The Cochrane Library Update 1998;2.
54. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994;50:1088-101.
55. Mulrow CD, Williams JW Jr, Trivedi M, Chiquette E, Aguilar C, Cornell JE. Treatment of Depression: Newer Pharmacotherapies. Evidence Report/ Technical Assessment No. 7. Rockville, MD: Agency for Health Care Policy and Research; February 1999. AHCPR Publication No. 99-E014.
56. Mulrow CD, Williams JW Jr, Trivedi M. Chiquette E, Aguilar C, Cornell JE, et al. Treatment of depression - newer pharmacotherapies. Psychopharmacol Bull. 1998;34:409-795.
57. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry. 1994;151:979-86.
58. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: American Psychiatric Pr; 1994.
59. Williams JW, Kerber CA, Mulrow CD, Medina A, Aguilar CA. Depressive disorders in primary care: prevalence, functional disability, and identification. J Gen Intern Med. 1995;10:7-12.
60. Coyne JC, Fechner-Bates S, Schwenk TL. Prevalence, nature, and comorbidity of depressive disorders in primary care. Gen Hosp Psychiatry. 1994; 16:267-76.
61. Callahan CM, Hendrie HC, Dittus RS, Brater DC, Hui SL, Tierney WM. Improving treatment of late life depression in primary care: a randomized clinical trial. J Am Geriatr Soc. 1994;42:839-46.
62. Persons JB, Thase ME, Crits-Cristoph P. The role of psychotherapy in the treatment of depression: review of two practice guidelines. Arch Gen Psychiatry. 1996;53:283-90.
63. Conte HR, Plutchik R, Wild KV, Karasu TB. Combined psychotherapy and pharmacotherapy for depression. A systematic analysis of the evidence. Arch Gen Psychiatry. 1986;43:471-9.
64. Persad E. Electroconvulsive therapy in depression. Can J Psychiatry. 1990; 35:175-82.
65. Sobin C, Prudic J, Devanand DP, Nobler MS, Sackeim HA. Who responds to electroconvulsive therapy? A comparison of effective and ineffective forms of treatment. Br J Psychiatry. 1996;169:322-8.
66. Peden JG Jr, Kathol R. Mood Disorders and General Medical Illness. v 1. Treatments of Psychiatric Disorders. 2d ed. Washington, DC: American Psychiatric Pr; 1995:1330-48.
67. Williams JW Jr, Rost K, Dietrich AJ, Ciotti MC, Zyzanski SJ, Cornell J. Primary care physicians' approach to depressive disorders: effects of physician specialty and practice structure. Arch Fam Med. 1999;8:58-67.
68. Egger M, Davey Smith G, Schneider M, Minder CE. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;314:629-34.
69. Warshaw MG, Keller MB. The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety disorders. J Clin Psychiatry. 1996;57:158-66.
70. Jick SS, Dean AD, Jick H. Antidepressants and suicide. BMJ. 1995;310: 215-8.
71. Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. BMJ. 1991;303:685-92.
72. Beasley CM Jr, Dornseif BE, Bosomworth JC, Sayler ME, Rampey AH Jr, Heiligenstein JH, et al. Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression. Int Clin Psychopharmacol. 1992;6(Suppl 6):35-7.
73. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H. Review of fluvoxamine safety database. Drugs. 1992;43(Suppl 2):48-53.
74. Lopez Ibor JJ Jr. Reduced suicidality with paroxetine. Eur Psychiatry. 1993; 8(Suppl 1):17s-19s.
75. Tollefson GD, Rampey AH Jr, Beasley CM Jr, Enas GG, Potvin JH. Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression. J Clin Psychopharmacol. 1994;14:163-9.
76. Goldstein DJ, Wilson MG. Adverse event frequencies generate hypotheses of efficacy and safety. Clin Pharmacol Ther. 1993;54:245-51.
77. Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry. 1985;46(3 Pt 2):59-67.
78. Henry JA, Alexander CA, Sener EK. Relative mortality from overdose of antidepressants. BMJ. 1995;310:221-4.
79. Kapur S, Mieczkowski T, Mann JJ. Antidepressant medications and the relative risk of suicide attempt and suicide. JAMA. 1992;268:3441-4.
80. Franchini L, Gasperini M, Perez J, Smeraldi E, Zanardi R. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry. 1997;58: 104-7.
81. Franchini L, Gasperini M, Smeraldi E. A 24-month follow-up study of unipolar subjects: a comparison between lithium and fluvoxamine. J Affect Disord. 1994;32:225-31.
82. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol. 1993;8:189-95.
83. Thase ME, Fava M, Halbreich U, Kocsis JH, Koran L, Davidson J, et al. A placebo-controlled, randomized clinical trial comparing sertraline and imipramine for the treatment of dysthymia. Arch Gen Psychiatry. 1996;53: 777-84.
84. Vanelle JM, Attar-Levy D, Poirier MF, Bouhassira M, Blin P, Olie JP. Controlled efficacy study of fluoxetine in dysthymia. Br J Psychiatry. 1997; 170:345-50.
85. Hellerstein DJ, Yanowitch P, Rosenthal J, Samstag LW, Maurer M, Kasch K, et al. A randomized double-blind study of fluoxetine versus placebo in the treatment of dysthymia. Am J Psychiatry. 1993;150:1169-75.
86. Boyer P, Lecrubier Y. Atypical antipsychotic drugs in dysthymia: placebo controlled studies of amisulpride versus imipramine versus amineptine. Eur Psychiatry. 1996;11(Suppl 3):135S-140S.
87. Salzmann E, Robin JL. Multicentric double-blind study comparing efficacy and safety of minaprine and imipramine in dysthymic disorders. Neuropsychobiology. 1995;31:68-75.
88. Smeraldi E. Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission: a double-blind, comparative study. J Affect Disord. 1998;48:47-56.
89. Parnetti L, Sommacal S, Morselli LA, Senin U. Multicentre controlled randomised double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Invest. 1993;6:181-8.
90. Szegedi A, Wetzel H, Angersbach D, Dunbar GC. Schwarze H, Philipp M, et al. A double-blind study comparing paroxetine and maprotiline in depressed outpatients. Pharmacopsychiatry. 1997;30:97-105.
91. Van Moffaert M, Vogels C, Beckers G, Vereecken A. Moclobemide versus amitriptyline in the treatment of depression: two double blind multicenter studies in Belgium. New Trends in Experimental and Clinical Psychiatry. 1989;5:167-77.
92. Hornig M. Hypericum for treatment of depression. Alternative Medicine Alert. 1998;1:4-7.
93. Ditzler K, Gessner B, Schatton WF, Willems M. Clinical trial on neuropas versus placebo in patients with mild to moderate depressive symptoms: a placebo-controlled, randomised double-blind study. Complement Ther Med. 1994;2:5-13.
94. Hoffmann J, Kuhl ED. Therapy of depressive states with hypericin [Therapie von depressiven Zustanden mit Hypericin]. ZFA (Stuttgart). 1979;55:776-82.
95. Reh C, Laux P, Schenk N. [Hypericum extract: An effective alternative in the treatment of depression]. [German]. Therapiewoche. 1992;42:1576-81.
96. Schmidt U, Sommer H. St. John's wort extract in the ambulatory therapy of depression. Attention and reaction ability are preserved. [Johanneskraut-Extract zur ambulanten Therapie der Depression. Aufmerksamkeit und Reaktionsvermogen bleiben erhalten]. Fortschr Med. 1993;111:339-42.
97. Witte B, Harrer G, Kaptan T, Podzuweit H, Schmidt U. Treatment of depressive symptoms with a high concentration hypericum preparation. A multicenter, placebo-controlled double-blind study [Behandlung depressiver Verstimmungen mit einem hochkonzentrierten Hypericumpraparat]. Fortschr Med. 1995;113:404-8.
98. Bergmann R, Nussner J, Demling J. Therapy of minor and moderate depressions. TW Neurologie Psychiatrie. 1993;7235-40.
99. Kniebel R, Burchard JM. Antidepressive therapy in practice. Zeitschrift fur Allgemeinmedizin. 1988;64:689-96.
100. Steger W. Depressive Verstimmungen. Zeitschrift fur Allgemeinmedizin. 1985;61:914-8.
101. Vorbach EU, Arnoldt KH, Hubner WD. Efficacy and tolerability of St. John's wort extract LI 160 versus imipramine in patients with severe depressive episodes according to ICD-10. Pharmacopsychiatry. 1997;30(Suppl 2): 81-5.
102. Vorbach EU, Hubner WD, Arnoldt KH. Effectiveness and tolerance of the hypericum extract LI 160 in comparison with imipramine: randomized double-blind study with 135 outpatients. J Geriatr Psychiatry Neurol. 1994; 7(Suppl 1):S19-S23.
103. Wheatley D. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry. 1997;30(Suppl 2):77-80.
104. Philipp M, Kohnen R, Hiller KO. Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. BMJ. 1999;319:1534-8.
105. Simeon JG, Dinicola VF, Ferguson HB, Copping W. Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:791-5.
106. Emslie GJ, Rush AJ, Weinberg WA, Kowatch RA, Hughes CW, Carmody T, et al. A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Arch Gen Psychiatry. 1997;54:1031-7.
107. Mandoki MW, Tapia MR, Tapia MA, Sumner GS, Parker JL. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull. 1997;33:149-54.
108. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, et al. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. JAMA. 1996;275:1897-902.
109. Rost K, Nutting P, Smith J, Werner J. Primary care intervention improves depression outcomes. Int J Psychiatry Med. 1998;28:398-9.
110. Katzelnick D, Simon G, Pearson S, Manning W, Helstad C, Henk H, et al. Randomized trial of depression management program in high utilizers of medical care. Int J Psychiatry Med. 1998;28:391-2.
111. Hunkeler E, Meresman J, Fireman B, Getzeil M, Feigenbaum P, Groebe J, et al. The efficacy of nurse telephone follow-up and peer support in treating depression in primary care. Int J Psychiatry Med. 1998;28:369-70.
112. Katon W, Von Korff M, Lin E, Walker E, Simon GE, Bush T, et al. Collaborative management to achieve treatment guidelines. Impact on depression primary care. JAMA. 1995;273:1026-31.
113. Lin EH, Von Korff M, Katon W, Bush T, Simon GE, Walker E, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care. 1995;33:67-74.
114. Donoghue J, Tylee A, Wildgust H. Cross sectional database analysis of antidepressant prescribing in general practice in the United Kingdom, 1993-5. BMJ. 1996;313:861-2.
115. Simon GE, VonKorff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry. 1993;15:399-408.
116. Katon W, von Korff M, Lin E, Bush T, Ormel J. Adequacy and duration of antidepressant treatment in primary care. Med Care. 1992;30:67-76.